Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BDTX Black Diamond Therapeutics	$2.79 +0.7%	$2.64	$1.20 ▼ $6.75	$158.86M	2.87	2.01 million shs	1.08 million shs
BHST BioHarvest Sciences	$9.22 -2.8%	$7.31	$4.66 ▼ $9.64	$151.44M	0.68	15,216 shs	9,834 shs
MCRB Seres Therapeutics	$16.86 +5.6%	$11.55	$6.53 ▼ $26.40	$147.53M	2.9	98,522 shs	208,877 shs
PVCT Provectus Biopharmaceuticals	$0.09 +0.5%	$0.08	$0.07 ▼ $0.15	$36.73M	0.57	193,316 shs	27,416 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BDTX Black Diamond Therapeutics	+9.06%	+2.97%	-5.78%	+43.52%	-48.32%
BHST BioHarvest Sciences	+4.17%	+20.13%	+34.61%	+47.59%	+948,999,900.00%
MCRB Seres Therapeutics	+3.43%	+15.89%	+7.54%	+115.52%	-3.56%
PVCT Provectus Biopharmaceuticals	+0.12%	+3.20%	+18.85%	+4.82%	-1.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BDTX Black Diamond Therapeutics	3.2484 of 5 stars	3.5	1.0	0.0	0.0	3.8	1.7	1.9
BHST BioHarvest Sciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MCRB Seres Therapeutics	3.0403 of 5 stars	2.9	1.0	0.0	4.6	2.0	0.8	0.0
PVCT Provectus Biopharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BDTX Black Diamond Therapeutics	3.00	Buy	$12.40	344.44% Upside
BHST BioHarvest Sciences	3.00	Buy	$13.67	48.23% Upside
MCRB Seres Therapeutics	1.75	Reduce	$73.67	336.93% Upside
PVCT Provectus Biopharmaceuticals	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest PVCT, MCRB, BHST, and BDTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
8/11/2025	BDTX Black Diamond Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $10.00
7/1/2025	BDTX Black Diamond Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform	$11.00

(Data available from 8/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BDTX Black Diamond Therapeutics	N/A	N/A	N/A	N/A	$2.33 per share	N/A
BHST BioHarvest Sciences	$30.19M	5.02	N/A	N/A	($0.26) per share	-35.46
MCRB Seres Therapeutics	$126.32M	1.17	N/A	N/A	$3.76 per share	4.48
PVCT Provectus Biopharmaceuticals	$620K	59.25	N/A	N/A	($0.01) per share	-8.74

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BDTX Black Diamond Therapeutics	-$69.68M	$0.23	12.13	N/A	N/A	N/A	12.70%	9.58%	N/A
BHST BioHarvest Sciences	-$12.91M	-$0.70	N/A	N/A	N/A	-39.95%	-11,357.84%	-39.94%	N/A
MCRB Seres Therapeutics	$140K	-$4.60	N/A	N/A	N/A	N/A	-350.16%	-67.69%	N/A
PVCT Provectus Biopharmaceuticals	-$4.76M	N/A	0.00	∞	N/A	-815.81%	N/A	-644.80%	N/A

Latest PVCT, MCRB, BHST, and BDTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q2 2025	BHST BioHarvest Sciences	-$0.1075	-$0.15	-$0.0425	-$0.24	$8.53 million	$8.52 million
8/7/2025	Q2 2025	BDTX Black Diamond Therapeutics	-$0.25	-$0.19	+$0.06	-$0.19	N/A	N/A
8/6/2025	Q2 2025	MCRB Seres Therapeutics	-$2.72	-$2.27	+$0.45	-$2.27	$11.75 million	N/A
5/15/2025	Q1 2025	BHST BioHarvest Sciences	-$0.15	-$0.13	+$0.02	-$0.13	$8.93 million	$7.64 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BDTX Black Diamond Therapeutics	N/A	N/A	N/A	N/A	N/A
BHST BioHarvest Sciences	N/A	N/A	N/A	N/A	N/A
MCRB Seres Therapeutics	N/A	N/A	N/A	N/A	N/A
PVCT Provectus Biopharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BDTX Black Diamond Therapeutics	N/A	8.73	8.73
BHST BioHarvest Sciences	N/A	0.60	0.30
MCRB Seres Therapeutics	N/A	1.57	1.57
PVCT Provectus Biopharmaceuticals	N/A	0.11	0.11

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BDTX Black Diamond Therapeutics	95.47%
BHST BioHarvest Sciences	N/A
MCRB Seres Therapeutics	59.34%
PVCT Provectus Biopharmaceuticals	0.05%

Insider Ownership

Company	Insider Ownership
BDTX Black Diamond Therapeutics	5.97%
BHST BioHarvest Sciences	N/A
MCRB Seres Therapeutics	4.70%
PVCT Provectus Biopharmaceuticals	14.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BDTX Black Diamond Therapeutics	90	56.94 million	53.54 million	Optionable
BHST BioHarvest Sciences	N/A	16.43 million	N/A	N/A
MCRB Seres Therapeutics	330	8.75 million	8.34 million	Optionable
PVCT Provectus Biopharmaceuticals	4	420.28 million	358.50 million	Not Optionable

PVCT, MCRB, BHST, and BDTX Headlines

Recent News About These Companies

Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT) Sees Large Increase in Short Interest

August 6, 2025 | americanbankingnews.com

Provectus Biopharmaceuticals Announces Publication of Moffitt Cancer Center Research on PV-10 for Head and Neck Cancer - Morningstar

June 27, 2025 | morningstar.comM

Provectus Biopharmaceuticals Announces Publication of Moffitt Cancer Center Research on PV-10 for Head and Neck Cancer

June 26, 2025 | globenewswire.com

Provectus Biopharmaceuticals Announces Investor Webinar for 2025 Annual Meeting of Stockholders

June 9, 2025 | globenewswire.com

Croatia's Provectus Capital Partners opens office in Romania

April 24, 2025 | seenews.comS

Provectus announces $3M seed financing round for VisiRose

January 14, 2025 | markets.businessinsider.com

Provectus Biopharmaceuticals Announces Seed Financing for VisiRose, Provectus’s Spinoff Company for Rose Bengal-Based Eye Drugs

January 14, 2025 | markets.businessinsider.com

Provectus Biopharmaceuticals Announces Seed Financing for VisiRose, Provectus's Spinoff Company for Rose Bengal-Based Eye Drugs

January 14, 2025 | globenewswire.com

Provectus launches VisiRose, Provectus’s Founded Entity for pharmaceutical-grade rose bengal sodium-based treatments in ophthalmology

December 13, 2024 | pharmabiz.comP

Provectus announces the launch of VisiRose

December 12, 2024 | markets.businessinsider.com

VisiRose Introduces Revolutionary Therapy for Severe Eye Infections

December 10, 2024 | miamiherald.comM

Provectus Pharmaceuticals Aligns Leadership with Equity Grants

December 6, 2024 | markets.businessinsider.com

Provectus Pharmaceuticals to Reveal Key 2024 Updates

November 15, 2024 | markets.businessinsider.com

Provectus Biopharmaceuticals, Inc. (PVCT) Q4 2024 Earnings Call Transcript

November 14, 2024 | seekingalpha.com

Provectus Biopharmaceuticals Announces Investor Webinar for Fourth Quarter 2024 Conference Call

October 24, 2024 | manilatimes.netM

Provectus Biopharmaceuticals Announces Fourth Quarter 2024 Conference Call

October 10, 2024 | globenewswire.com

Provectus Biopharmaceuticals Announces Poster Presentation of Rose Bengal Sodium for Treatment of Full-Thickness Cutaneous Wounds at SID 2024 Annual Meeting

May 21, 2024 | finance.yahoo.com

Provectus Biopharmaceuticals Announces Eight Presentations of Rose Bengal Photodynamic Antimicrobial Therapy at ARVO 2024 Annual Meeting

May 14, 2024 | finance.yahoo.com

Provectus Biopharmaceuticals Announces Publication of Preclinical Data of Oral Administration of Provectus Rose Bengal for Solid Tumor Cancers

April 18, 2024 | finance.yahoo.com

Provectus Biopharmaceuticals Announces Management Additions and Reiterates Commitment to Shareholder Value Creation

April 16, 2024 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PVCT, MCRB, BHST, and BDTX Company Descriptions

Black Diamond Therapeutics NASDAQ:BDTX

$2.79 +0.02 (+0.72%)

Closing price 04:00 PM Eastern

Extended Trading

$2.78 -0.02 (-0.54%)

As of 04:11 PM Eastern

Black Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

BioHarvest Sciences NASDAQ:BHST

$9.22 -0.27 (-2.85%)

As of 03:27 PM Eastern

BioHarvest Sciences Inc. is a biotech firm. It focused on leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions, within business verticals nutraceutical health and wellness products such as dietary supplements and development of plant cell-based Active Pharmaceutical Ingredients which focus on specific medical indications. BioHarvest Sciences Inc. is based in Vancouver, Canada.

Seres Therapeutics NASDAQ:MCRB

$16.86 +0.89 (+5.57%)

Closing price 04:00 PM Eastern

Extended Trading

$17.09 +0.23 (+1.36%)

As of 04:10 PM Eastern

Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Provectus Biopharmaceuticals OTCMKTS:PVCT

$0.09 +0.00 (+0.46%)

As of 01:35 PM Eastern

Provectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes in the United States. The company's lead molecule is rose bengal sodium (RBS). Its clinical development programs include PV-10 for the treatment of stage III and IV melanoma and different types of liver cancers; PH-10 for the treatment of psoriasis and atopic dermatitis, and skin inflammation; and PV-305 for the treatment of infectious keratitis. It is also developing oral formulations for adult solid tumor cancers, as well as refractory and relapsed pediatric, and other blood cancers comprising leukemias; PV-10 for the treatment of relapsed and refractory pediatric solid tumor cancers; and other formulations for the treatment of cutaneous canine cancers and healing of full-thickness cutaneous wounds. In addition, the company develops oral and intranasal formulations for the treatment of severe acute respiratory syndrome coronavirus 2; gram-positive and gram-negative bacterial infections; oral bacterial infections; and fungal infections, as well as vertebrate development, wound healing, and tissue regrowth. It has collaboration agreement with Bascom Palmer Eye Institute; and University of Miami. The company was formerly known as Provectus Pharmaceuticals, Inc. and changed its name to Provectus Biopharmaceuticals, Inc. in December 2013. Provectus Biopharmaceuticals, Inc. was founded in 2002 and is based in Knoxville, Tennessee.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time